Vanda Pharmaceuticals VNDA - オプションチェーン

Vanda Pharmaceuticals Inc ([symbol]) オプションチェーン

オプションコール

行使価格	買値	売値	前回の価格	中間価格	建玉	最終取引
1.00	4.30	5.90	5.12	5.10	381	-
2.00	1.90	6.50	2.60	4.20	2	-
3.00	1.00	5.50	3.20	3.25	42	-
4.00	1.30	2.65	1.35	1.975	18	-
5.00	0.05	4.80	2.10	2.425	2	-
6.00	0.20	0.70	0.30	0.45	723	-
7.00	0.00	0.05	0.05	0.05	1,273	-
8.00	0.00	0.05	0.07	0.07	3,573	-
9.00	0.00	0.05	0.05	0.05	856	-
10.00	0.00	0.30	0.10	0.10	1,431	-
11.00	0.00	0.95	0.10	0.10	9	-
12.00	0.00	0.95	0.10	0.10	52	-
13.00	0.00	0.75	0.50	0.50	2	-
14.00	0.00	0.75	0.10	0.10	2	-
15.00	0.00	0.65	0.05	0.05	163	-

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

オプションプット

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
1.00	0.00	0.05	0.05	0.05	0.00	0.00 %	0	2	-
2.00	0.00	0.95	0.00	0.00	0.00	0.00 %	0	0	-
3.00	0.00	0.95	0.02	0.02	0.00	0.00 %	0	4	-
4.00	0.00	1.00	0.08	0.08	0.00	0.00 %	0	15	-
5.00	0.00	0.95	0.05	0.05	0.00	0.00 %	0	84	-
6.00	0.00	0.45	0.18	0.18	0.00	0.00 %	0	97	-
7.00	0.85	1.40	0.89	1.125	0.11	14.10 %	1	429	2026/6/12
8.00	0.25	2.60	2.07	1.425	0.00	0.00 %	0	3	-
9.00	0.90	5.50	2.76	3.20	0.00	0.00 %	0	102	-
10.00	1.60	6.40	2.85	4.00	0.00	0.00 %	0	6	-
11.00	2.50	7.40	0.00	4.95	0.00	0.00 %	0	0	-
12.00	3.70	8.40	4.19	6.05	0.00	0.00 %	0	0	-
13.00	4.50	9.40	0.00	6.95	0.00	0.00 %	0	0	-
14.00	5.50	10.40	0.00	7.95	0.00	0.00 %	0	0	-
15.00	6.50	11.40	6.90	8.95	0.00	0.00 %	0	0	-

銘柄コード	株価	出来高
GELSGelteq Ltd	US$ 1.54 (199.32%)	153.37M
QHQuhuo Ltd	US$ 7.4783 (130.10%)	15.06M
GLXGGalaxy Payroll Group Ltd	US$ 2.04 (108.99%)	113.89M
PPCBPropanc Biopharma Inc	US$ 2.44 (80.74%)	174.62M
EDHLEverbright Digital Holding Ltd	US$ 6.05 (72.86%)	65.38M
NTCLNetClass Technology Inc	US$ 0.399 (-86.29%)	57M
PPBTPurple Biotech Ltd	US$ 1.50 (-49.32%)	10.51M
DSYBig Tree Cloud Holdings Limited	US$ 3.80 (-47.22%)	1.26M
ATOSAtossa Therapeutics Inc	US$ 2.585 (-41.25%)	1.42M
PAVSParanovus Entertainment Technology Ltd	US$ 0.297 (-40.60%)	44.91M
ADTXAditxt Inc	US$ 0.013 (-29.73%)	656.14M
SMCISuper Micro Computer Inc	US$ 31.97 (9.22%)	251.86M
HKITHitek Global Inc	US$ 0.5522 (26.65%)	222.33M
INTCIntel Corporation	US$ 116.96 (9.27%)	188.47M
PPCBPropanc Biopharma Inc	US$ 2.44 (80.74%)	174.62M

銘柄コード

株価

出来高

ADTXAditxt Inc

US$ 0.013

(-29.73%)

656.14M

SMCISuper Micro Computer Inc

US$ 31.97

(9.22%)

251.86M

HKITHitek Global Inc

US$ 0.5522

(26.65%)

222.33M

INTCIntel Corporation

US$ 116.96

(9.27%)

188.47M

PPCBPropanc Biopharma Inc

US$ 2.44

(80.74%)

174.62M

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsMay 1, 2026 4:35 PM
PR Newswire (US)

Consumers can now order NEREUS™ directly at nereus.usWASHINGTON, May 1, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in adults, marking the first new prescription medicine approved for this condition in more than 40 years. An innovative direct-to-consumer order platform is now available through nereus.us.

Motion sickness affects an estimated 65 to 78 million Americans—roughly 25 to 30 percent of adults—during everyday travel by car, plane, or boat. For decades, patients have had no meaningful new treatment options. That changes today with NEREUS™, an oral neurokinin-1 (NK-1) receptor antagonist that offers a modern, targeted approach to a problem that has long lacked innovation."Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of Vanda. "NEREUS™ is a selective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1) receptors that can block the vomiting center of the brain. We are excited to make this innovative therapy available through both traditional pharmacy channels and our new direct-to-consumer platform at nereus.us, giving travelers, families, and anyone affected by motion sickness convenient access to a long-awaited solution."NEREUS™ is available now by prescription directly through nereus.us and retail pharmacies nationwide. Through the dedicated direct-to-consumer portal at nereus.us, patients with a valid prescription can access NEREUS™ at a cash-pay price of just $85 per dose, a meaningful discount from the standard list price of $255 per dose.Throughout history, motion sickness has repeatedly undermined military effectiveness and human exploration. During Napoleon's 1798 Egyptian campaign, soldiers in his newly formed camel corps—known as the "ships of the desert"—suffered debilitating nausea and vomiting from the animals' swaying gait, rendering many unfit for battle and even affecting Napoleon himself. On D-Day in 1944, thousands of Allied paratroopers endured violent air sickness during turbulent flights over the English Channel before they even reached Normandy. In the space age, nearly 70 percent of astronauts have faced space adaptation syndrome, a form of motion sickness that has challenged every major space program since the 1960s. For more than four decades, no new pharmacologic treatment emerged to address this ancient affliction—until today.Motion sickness may occur when the brain receives conflicting signals from the eyes, inner ear, and body while on motion. This sensory mismatch is believed to trigger the release of substance P, which activates NK-1 receptors in the central nervous system and ultimately leads to nausea and vomiting. NEREUS™ works by blocking these receptors, interrupting the vomiting pathway.The U.S. Food and Drug Administration approved NEREUS™ on December 30, 2025, following two pivotal Phase 3 clinical trials—Motion Syros and Motion Serifos—conducted under real-world conditions on the open sea. Both studies demonstrated that NEREUS™ significantly prevented vomiting compared to placebo, confirming the drug's effectiveness in actual sea travel conditions. It is the first new prescription option for people with history of motion sickness in over 40 years. It employs a novel mechanism as a selective, high-affinity antagonist of human substance P/NK-1 receptors. It offers simple dosing with just one or two capsules a day taken approximately an hour before travel.The commercial availability of NEREUS™ marks a historic milestone in addressing this highly prevalent physiological reaction to motion that has plagued humans for millennia.Visit nereus.us to access the direct-to-consumer portal and learn more about NEREUS™.About Vanda PharmaceuticalsVanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.About NEREUS™Indication and Important Safety Information for NEREUS™ (tradipitant) capsules.INDICATIONNEREUS™ (NEER-ee-us) [tradipitant] is a prescription medication used for the prevention of vomiting induced by motion in adults.IMPORTANT SAFETY INFORMATIONNEREUS™ may impair abilities required for driving a motor vehicle or operating heavy machinery. Combining NEREUS™ with sedatives or medications that increase NEREUS™ levels may increase this effect. If use together cannot be avoided, your doctor may warn against driving or operating heavy machinery.The most common side effects associated with NEREUS™ include drowsiness, headache, and fatigue.Tell your healthcare provider about all of the medicines you're taking. Strong CYP3A4 inhibitors may increase NEREUS™ levels and the risk of side effects.Tell your healthcare provider about all of your health conditions, including if you have liver or kidney problems, or if you are pregnant, planning to become pregnant, or breastfeeding. There are limited data on NEREUS™ use in pregnant women.Monitor breastfed infants for drowsiness.The safety and effectiveness of NEREUS™ for the prevention of vomiting induced by motion in children have not been established.NEREUS™ is not recommended in patients with liver problems or severe kidney problems.Consumer Important Safety InformationYou are encouraged to report side effects of prescription drugs to the FDA. To report side effects, contact Vanda Pharmaceuticals Inc. at 1-844-GO-VANDA (1-844-468-2632) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.For more information, ask your healthcare provider or call 1-844-468-2632.This information does not take the place of talking with your healthcare provider for medical advice about your condition or treatment.Download the full US Prescribing Information at nereus.us.NEREUS™ (tradipitant) is a neurokinin-1 receptor antagonist FDA approved for the acute prevention of vomiting induced by motion in adults, and is currently in clinical development for a variety of other indications, including gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. For full Prescribing Information and other resources, please visit nereus.us.CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this press release, including, but not limited to statements regarding the prevalence of motion sickness; the potential causes of motion sickness and the ways in which it may be triggered; and Vanda's further clinical development plans for NEREUS™ for various indications, including gastroparesis and vomiting induced by GLP-1 receptor agonists are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the accuracy of the estimates of the prevalence of motion sickness; Vanda's assumptions regarding the causes of motion sickness and the ways in which it may be triggered; and Vanda's ability to continue to advance tradipitant in gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Corporate Contact:Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.comJim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-us-commercial-availability-of-nereus-tradipitant-the-first-new-pharmacologic-treatment-for-people-with-motion-sickness-in-more-than-40-years-302760461.htmlSOURCE Vanda Pharmaceuticals Inc.

Original: Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular PsoriasisFebruary 25, 2026 7:18 AM
PR Newswire (US)

WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026.

GPP is a rare, chronic, life-threatening autoinflammatory skin disorder characterized by sudden flares of widespread pustules, erythema, and systemic symptoms such as fever and fatigue. The pathogenesis of GPP is increasingly understood through its genetic characterization (OMIM #614204), and its molecular etiology is mainly attributed to excessive activity of the interleukin-36 (IL-36) pathway.1 The majority of GPP cases for which a causal single gene defect has been identified are caused by various consequential genetic variants in the IL36RN gene, encoding the IL-36 receptor antagonist (IL-36Ra).2,3,4Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is believed to achieve its therapeutic effects in GPP where IL-36 signaling is unbalanced. If approved, imsidolimab could address a significant unmet medical need in this rare and life-threatening disorder with potential benefits over currently existing treatments.Imsidolimab was studied in global clinical studies conducted in the United States, France, Spain, Poland, Turkey, Malaysia, Thailand, Georgia, Tunisia, Taiwan, and Morocco. In the pivotal efficacy studies GEMINI-1 and GEMINI-2, a single intravenous dose of imsidolimab led to rapid disease clearance, with 53% of patients achieving clear or almost clear skin (GPPPGA 0/1) at Week 4 compared to 13% on placebo. Efficacy was maintained throughout an approximately 2-year maintenance period with monthly doses, and no flares occurred in the active treatment arm. Imsidolimab exhibited a favorable safety profile and demonstrated a low incidence of anti-drug antibodies, which can be a significant advantage over existing treatments. GPP is a rare disorder with prevalence estimates varying widely by region, ranging from approximately 2 to 124 cases per million worldwide (lower in Europe and higher in parts of Asia).5,6"The acceptance of the BLA filing for imsidolimab marks a critical milestone in our efforts to bring this innovative therapy to patients suffering from GPP," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals. "Imsidolimab builds on our growing expertise in rare orphan disorders and our anti-inflammatory portfolio. Imsidolimab represents a precision medicine approach targeting a disorder with a known genetic cause using a fully humanized monoclonal antibody against the IL-36 receptor. We look forward to potential FDA approval and leveraging our commercial infrastructure to address this debilitating condition."Vanda celebrates this significant milestone for imsidolimab's acceptance for review by the FDA during Rare Disease Week on Capitol Hill (February 24–26, 2026), as advocates unite to promote innovation and access to treatments for rare orphan diseases like generalized pustular psoriasis.If imsidolimab is approved, it will be the third new drug product approved for Vanda in the past 12 months, following NEREUS™ (tradipitant) and BYSANTI™ (milsaperidone).ReferencesOnline Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number: 614204: 12/16/2020. Available at: https://omim.org/Marrakchi, S. et al. Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis. New England Journal of Medicine 365, 620–628 (2011).Sugiura, K. et al. The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist. Journal of Investigative Dermatology 133, 2514–2521 (2013).Johnston, A. et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. Journal of Allergy and Clinical Immunology 140(1), 109–120 (2017).Sachen, K. L. et al. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine 156, 155897 (2022).Prinz, J. C. et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review. Journal of the European Academy of Dermatology and Venereology 37, 256–273 (2022).About ImsidolimabImsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s. Vanda holds an exclusive global license for the development and commercialization of imsidolimab from AnaptysBio (Nasdaq: ANAB).About Vanda PharmaceuticalsVanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this press release, including, but not limited to statements regarding the anticipated timing of the completion of the FDA's review of the imsidolimab BLA; imsidolimab's mechanism of action; the potential for imsidolimab to address a significant unmet medical need; the prevalence of GPP; potential FDA approval of imsidolimab; Vanda's plans to leverage its commercial infrastructure to address GPP; and the potential to extend regulatory and patent exclusivity for imsidolimab into the late 2030s, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the FDA's ability to complete its review of, and reach a decision with respect to, the imsidolimab BLA by December 12, 2026; Vanda's assumptions regarding how imsidolimab achieves its therapeutic effect; Vanda's ability to obtain FDA approval of imsidolimab for the treatment of GPP; Vanda's ability to successfully execute the commercial launch of imsidolimab and to leverage its commercial infrastructure to reach patients with GPP; the ability of imsidolimab to safely and effectively treat GPP; the accuracy of the estimates of the prevalence of GPP; and Vanda's ability to satisfy the conditions necessary to extend regulatory and patent exclusivity for imsidolimab into the late 2030s. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.comJim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.htmlSOURCE Vanda Pharmaceuticals Inc.

Original: Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis